Thus, the circulating SELENOP, as a negative acute-phase reactant and a hepatokine, could be downregulated by both inflammation [51,100,101,102] and decreased selenoprotein synthetic capacity in the MetS status. This evidence concerns the gene SELENOP and metabolic syndrome.